Business Standard

Transgene Biotek Share Price

Know More
Stock not traded

7.68-0.38 (-4.71%)

12:00 AM,12th Apr 2024

BSE : 526139


Sector : Health care

ISIN Code : INE773D01018

  • NSE
  • BSE
  • 1D
  • 5D
  • 1M
  • 6M
  • 1Y
  • 2Y
  • 5Y
  • MAX

Last Updated: Apr 12 2024 | 12:00 AM IST

Market Cap (₹ Cr)


Turnover (₹ Cr)


Volume (Shares)

Face Value


52-WK High


52-WK High Date

Invalid date

52-WK Low


52-WK Low Date

Invalid date

All Time High


All Time High Date

Invalid date

All Time Low


All Time Low Date

Invalid date

Transgene Biotek Ltd

Founded in March 1990 by Dr. Koteswara Rao Transgene Biotek Ltd was one of the first Biotechnology companies in India. Although Transgene began life manufacturing and selling diagnostic kits it soon moved on to true biotech research including the research and development of vaccines oncology New drug delivery technologies etc. The first major success came when it sold genetically engineered recombinant Hepatitis B vaccine technology along with novel and patented process in 1999 to the Serum Institute Pune.Presently the Company is engaged in the business of research and development and manufacture of various medical reagents both chemical and immuno-diagnostic reagents for qualitative and quantitative estimation of bio-chemical parameters and diagnosis of diseases respectively.Transgene Biotek's products are exported to Africa Russia China Malaysia and the Phillipines. The company chalked out a new project for setting up a manufacturing facility costing Rs. 30 crore at the Anrich Industrial Area Bollaram. TBL is working of four new plants comprising of Oral deliver of proteins and peptides; DNA vaccines; fusion proteins and bio therapeutics. The new project is funded through preferential offer to Batterymarch Financial Management USA and Other Financial Institutions (FIs).The Company absorbed the transfer of technology from RBB Inc USA for the manufacture and marketing of Erythropoietin during year 2003. The Scheme of Arrangement for Amalgamation of M/S Saket Biotechnologies Private Limited (SBPL) with the Company was implemented and made effective on 7th February 2005. In terms of the said Scheme of Amalgamation 6060000 Equity Shares were allotted to the Sharesholders of M/S Saket Biotechnologies Private limited on 27 April 2005.In 2012-13 the Company started the commercial production of Omega-3 DHA (Docosahexaenoic Acid) . It formulated the molecule belonging to a very large global pharma company for undergoing studies at its own chosen facilities in USA during year 2020-21. Transgene has been developing novel oral and nasal formulations for the delivery of various protein and peptide-based biologicals through oral and intra-nasal routes. Transgene is focused on developing novel therapies in the areas of Oncology Auto-Immune diseases and new drug delivery technologies that have the potential to substantially improve the quality of life of patients in areas of unmet medical need.

Transgene Biotek Ltd - Key Fundamentals

Market Cap (₹ Cr)


EPS - TTM (₹) [S]


P/E Ratio (X) [S]


Face Value (₹) 10
Latest Dividend (%)-
Latest Dividend Date -
Dividend Yield (%) -
Book Value Share (₹) [S]-0.86
P/B Ratio (₹) [S]-8.93
[*C] Consolidated [*S] Standalone

Funds Owing this Stock

Scheme Name Amount Invested ( ₹ Cr ) No Of Shares Net Asset (%)

Research Reports

Date BrokerActionPrices(Rs)Report
Data Not Found

Stock Strength

Today's Low/High



Week Low/High



Month Low/High



Year Low/High



All time Low/High



Share Price Returns

1 Week0.13%%0.000.03%
1 Month-20.41%%0.780.82%
3 Month-13.61%%2.312.85%
6 Month85.51%%11.8013.77%
1 Year201.18%%22.9426.43%
3 Year36.90%%55.0557.36%

Company Info

Company Information

Independent Director : Sujana Kadiam

Company Sec. & Compli. Officer : Ankita Jain

Independent Director : Santosh Kumar

Chairman & Managing Director : K Koteswara Rao

Independent Director : Marri Swetha

Registered Office: Plot No 69 & 70 IDA Bollaram, ,Sangareddy,Telangana-502325 Ph: